Evidence map›Paper›PMID 29093811›Full record

ArticleRSC advances2016

Precision Microfilters as an all in one System for Multiplex Analysis of Circulating Tumor Cells.

Daniel L Adams, R Katherine Alpaugh, Stuart S Martin, Monica Charpentier, Saranya Chumsri, Massimo Cristofanilli, Diane K Adams, Olga V Makarova, Peixuan Zhu, Shuhong Li and 2 more

Abstract read
In one paragraph

Article in RSC advances, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Blood-based biopsies-clinical utility beyond circulating tumor cells.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2018
    Article
  9. Article
  10. Article
  11. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.Annals of oncology : official journal of the European Society for Medical Oncology · 2017
    Review
  12. Article
  13. Article
  14. Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Daniel L AdamsCreatv MicroTech, Inc., 1 Deer Park Dr., Monmouth Junction, NJ 08852.
R Katherine AlpaughFox Chase Cancer Center, Protocol Support Laboratory, 333 Cottman Ave., Philadelphia, PA 19111.
Stuart S MartinUniversity of Maryland Baltimore Greenebaum Cancer Center, 655 W. Baltimore St., Baltimore, MD 21136.
Monica CharpentierUniversity of Maryland Baltimore Greenebaum Cancer Center, 655 W. Baltimore St., Baltimore, MD 21136.
Saranya ChumsriUniversity of Maryland Baltimore Greenebaum Cancer Center, 655 W. Baltimore St., Baltimore, MD 21136.
Massimo CristofanilliRobert H Lurie Comprehensive Cancer Center, Northwestern University, 645 N Michigan Avenue, Chicago, IL 60611.
Diane K AdamsRutgers, the State University of New Jersey, 71 Dudley Rd., New Brunswick, NJ 08901.
Olga V MakarovaCreatv MicroTech, Inc., 2242 West Harrison St., Chicago IL, 60612.
Peixuan ZhuCreatv MicroTech, Inc., 9900 Belward Campus Dr. Rockville, MD 20850.
Shuhong LiCreatv MicroTech, Inc., 9900 Belward Campus Dr. Rockville, MD 20850.
Cha-Mei TangCreatv MicroTech, Inc., 9900 Belward Campus Dr. Rockville, MD 20850.
Steingrimur StefanssonHememics Biotechnologies, 12111 Parklawn Dr. Rockville MD, 20852.

Funding

Targeting microtubule stabilization to reduce breast tumor metastasisR01CA154624 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI MARTIN, STUART S · 2012 to 2023
$3.4M
NCI NIH HHS R01 CA154624
6 · The paper itself

Abstract

Enumeration of circulating tumor cells (CTCs) from cancer patient blood is an established diagnostic assay used to evaluate patient status as a singleplex test. However, in the coming age of personalized medicine, multiplex analysis of patient CTCs, including proteomic and genomic techniques, will have to be integrated with CTC isolation platform technologies. Advancements in microfabrication have demonstrated that CTCs can be isolated and analyzed using microfluidic lab-on-a-chip devices. However, to date, most microfluidic devices are either still in the development phase, not applicable to all clinical tests, or are not commercially available. To overcome these discrepancies, we describe an all-in-one device for the isolation and multiplexing of clinically applicable CTC assays. Microfilters present an ideal lab-on-a-chip platform for analysis of CTCs as non-toxic and inert materials allow for a multitude of tests from cell growth through clinical staining techniques, all without background interference. Lithographically fabricated microfilters, can be made with high porosity, precise pore dimensions, arrayed pore distribution, and optimized for CTC size-based isolation. In this study we describe microfilter use in isolation and

Identifiers

PMID29093811
PMCPMC5662211

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.